Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company’s runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its cash runway through Q3 2026 Seres will focus on advancing deve...
A director at Snap Inc sold/gave away 2,601,453 shares at 0.000USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call . A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “In...
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026Strong EMPAVELI® (pegcetacoplan) launch in C3G and primary IC-MPGN continues, with 267 new patient start forms in 2025; more than 5% market penetration following the first full quarter post-launchPivotal trials initiated for EMPAVELI in two additional nephrology in...
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres’ portfolio, including Phase 2-ready lead candidate SER-155 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq...
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 11:15 a.m. PT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals,...
A director at International Flavors & Fragrances Inc bought 3,100 shares at 63.480USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent results across adolescent and adult patients with C3G and primary IC-MPGN, including patients with C3G recurring after transplantEMPAVELI is the first FDA-approved treatment for C3G and primary IC-MPGN patients 12 and older WALTHAM, Mass., Dec. 03, 2025 (GLOB...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.